HomeAI · summaries
Storia in 5 fonti
A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
- ·
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
- ·
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
- ·
fiercebiotech.com
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…
- ·
fiercepharma.com
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…
- ·
A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
- ·
A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
- ·
Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
- ·
endpoints.news
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
- ·
pharmaceutical-technology.com
ASCO26: In vivo oncology approaches continue to show promise
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
- ·
As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that…
- ·
Legend Biotech emerged as a rare market winner
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout